We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FocalTherics (FOCL) Surges 6.2%: Is This an Indication of Further Gains?
Read MoreHide Full Article
FocalTherics (FOCL - Free Report) shares rallied 6.2% in the last trading session to close at $6.34. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.4% gain over the past four weeks.
FocalTherics scored a strong price increase on investors’ optimism surrounding the company’s impending second quarter 2026 financial results, which is set to release on Aug. 13. Per the Zacks Consensus Estimate, the company’s quarterly revenues are pegged at $11.89 million. Loss per share is pegged at 20 cents for the second quarter.
This company is expected to post quarterly loss of $0.20 per share in its upcoming report, which represents a year-over-year change of -17.7%. Revenues are expected to be $11.89 million, down 35.5% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For FocalTherics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on FOCL going forward to see if this recent jump can turn into more strength down the road.
FocalTherics is a member of the Zacks Medical - Instruments industry. One other stock in the same industry, Lucid Diagnostics Inc. (LUCD - Free Report) , finished the last trading session 1% lower at $0.96. LUCD has returned -10.3% over the past month.
For Lucid Diagnostics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.04. This represents a change of +60% from what the company reported a year ago. Lucid Diagnostics currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
FocalTherics (FOCL) Surges 6.2%: Is This an Indication of Further Gains?
FocalTherics (FOCL - Free Report) shares rallied 6.2% in the last trading session to close at $6.34. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.4% gain over the past four weeks.
FocalTherics scored a strong price increase on investors’ optimism surrounding the company’s impending second quarter 2026 financial results, which is set to release on Aug. 13. Per the Zacks Consensus Estimate, the company’s quarterly revenues are pegged at $11.89 million. Loss per share is pegged at 20 cents for the second quarter.
This company is expected to post quarterly loss of $0.20 per share in its upcoming report, which represents a year-over-year change of -17.7%. Revenues are expected to be $11.89 million, down 35.5% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For FocalTherics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on FOCL going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
FocalTherics is a member of the Zacks Medical - Instruments industry. One other stock in the same industry, Lucid Diagnostics Inc. (LUCD - Free Report) , finished the last trading session 1% lower at $0.96. LUCD has returned -10.3% over the past month.
For Lucid Diagnostics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.04. This represents a change of +60% from what the company reported a year ago. Lucid Diagnostics currently has a Zacks Rank of #3 (Hold).